NovaBridge Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	210.63	68.26	291.51	465.99	554.68
Short-Term Investments	0.21	105.14	20.22	34.8	118.56
Cash & Short-Term Investments	210.84	173.4	311.73	500.78	673.24
Cash Growth	21.59%	-44.38%	-37.75%	-25.61%	-8.25%
Accounts Receivable	-	-	-	-	45.16
Other Receivables	1.79	1.17	1.83	4.81	16
Receivables	1.79	1.17	1.83	4.81	61.16
Inventory	-	-	-	-	4.29
Prepaid Expenses	0.7	1.13	0.12	1.38	1.41
Restricted Cash	-	-	-	14.03	-
Other Current Assets	4.19	1	16.23	4.78	12.62
Total Current Assets	217.52	176.69	329.91	525.79	752.72
Property, Plant & Equipment	2.95	3.8	5.55	17.97	24.95
Long-Term Investments	37.24	30.82	-	4.47	55.43
Goodwill	-	-	-	23.57	25.59
Other Intangible Assets	-	-	-	17.24	18.84
Other Long-Term Assets	2.81	1.37	33.46	1.58	4.19
Total Assets	260.52	212.68	368.92	590.63	881.72
Accrued Expenses	16.82	7.53	6.58	100.48	92.27
Short-Term Debt	-	-	-	2.75	-
Current Portion of Leases	0.89	0.82	0.63	3.47	4.83
Current Unearned Revenue	-	-	-	1.26	-
Other Current Liabilities	9.18	0.11	50.94	1.96	1.13
Total Current Liabilities	26.89	8.45	58.14	109.92	98.23
Long-Term Leases	2.18	3.07	3.26	4.65	12.87
Long-Term Unearned Revenue	-	-	-	38.84	35.26
Other Long-Term Liabilities	0.51	-	64.93	15.32	17.61
Total Liabilities	29.58	11.52	126.34	168.73	163.97
Common Stock	0.03	0.02	0.02	0.02	0.02
Additional Paid-In Capital	1,527	1,460	1,475	1,389	1,433
Retained Earnings	-1,332	-1,286	-1,264	-994.92	-685.52
Treasury Stock	-5.04	-6.23	-8.01	-3.08	-
Comprehensive Income & Other	41.55	33.38	39.77	31	-29.36
Total Common Equity	230.94	201.16	242.58	421.9	717.75
Shareholders' Equity	230.94	201.16	242.58	421.9	717.75
Total Liabilities & Equity	260.52	212.68	368.92	590.63	881.72
Total Debt	3.07	3.88	3.89	10.87	17.7
Net Cash (Debt)	207.78	169.52	307.84	489.91	655.53
Net Cash Growth	22.57%	-44.93%	-37.16%	-25.26%	-10.41%
Net Cash Per Share	2.17	2.09	3.70	5.94	8.63
Filing Date Shares Outstanding	115.65	81.5	80.7	82.99	82.55
Total Common Shares Outstanding	115.38	81.5	80.7	82.99	79.92
Working Capital	190.63	168.24	271.77	415.87	654.49
Book Value Per Share	2.00	2.47	3.01	5.08	8.98
Tangible Book Value	230.94	201.16	242.58	381.09	673.32
Tangible Book Value Per Share	2.00	2.47	3.01	4.59	8.42
Machinery	-	-	1.77	9.33	6.1
Construction In Progress	-	-	-	0.9	3.32
Leasehold Improvements	-	-	0.87	5.42	2.98

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q